blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3407889

EP3407889 - ORGANIC COMPOUNDS AND THEIR USE IN TREATING OR PREVENTING CENTRAL NERVOUS SYSTEM DISORDERS [Right-click to bookmark this link]
Former [2018/49]ORGANIC COMPOUNDS
[2020/52]
StatusNo opposition filed within time limit
Status updated on  25.03.2022
Database last updated on 26.06.2024
FormerThe patent has been granted
Status updated on  16.04.2021
FormerGrant of patent is intended
Status updated on  07.12.2020
FormerExamination is in progress
Status updated on  02.03.2019
FormerRequest for examination was made
Status updated on  02.11.2018
FormerThe international publication has been made
Status updated on  30.09.2017
Most recent event   Tooltip03.05.2024Lapse of the patent in a contracting state
New state(s): MK		published on 05.06.2024  [2024/23]
Applicant(s)For all designated states
Intra-Cellular Therapies, Inc.
430 East 29th Street, Suite 900
New York, NY 10016 / US
[2018/49]
Inventor(s)01 / YAO, Wei
Intra-Cellular Therapies Inc.
430 East 29th Street
Suite 900
New York, New York 10016 / US
02 / LI, Peng
Intra-Cellular Therapies Inc.
430 East 29th Street
Suite 900
New York, New York 10016 / US
 [2018/49]
Representative(s)Synergy IP Group AG
Leonhardsgraben 52
Postfach
4001 Basel / CH
[N/P]
Former [2021/20]Pharma Patents International AG
Leonhardsgraben 52
4051 Basel / CH
Former [2018/49]Pharma Concepts GmbH
Unterer Rheinweg 50
4057 Basel / CH
Application number, filing date17771285.824.03.2017
[2018/49]
WO2017US24137
Priority number, dateUS201662313629P25.03.2016         Original published format: US 201662313629 P
[2018/49]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017165843
Date:28.09.2017
Language:EN
[2017/39]
Type: A1 Application with search report 
No.:EP3407889
Date:05.12.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 28.09.2017 takes the place of the publication of the European patent application.
[2018/49]
Type: B1 Patent specification 
No.:EP3407889
Date:19.05.2021
Language:EN
[2021/20]
Search report(s)International search report - published on:US28.09.2017
(Supplementary) European search report - dispatched on:EP13.02.2019
ClassificationIPC:A61K31/4985, A61K31/5383, A61K31/519, A61P25/28, A61P25/18, A61P25/24, A61P25/00, A61K45/06, C07D471/14
[2020/52]
CPC:
A61K31/519 (EP,IL,US); A61K31/4985 (EP,CN,IL,KR,RU,US); C07D471/14 (EP,IL,KR,RU,US);
C07D471/16 (CN); A61K31/5383 (RU); A61K45/06 (EP,CN,IL,KR,US);
A61K9/0004 (EP,IL); A61P1/00 (CN,KR); A61P25/00 (EP,CN,IL,KR,RU,US);
A61P25/06 (CN); A61P25/14 (CN); A61P25/16 (CN);
A61P25/18 (EP,CN,IL,US); A61P25/20 (CN); A61P25/22 (CN);
A61P25/24 (EP,CN,IL,US); A61P25/28 (EP,CN,IL,RU,US); A61P3/04 (CN,KR);
A61K2300/00 (IL) (-)
C-Set:
A61K31/4985, A61K2300/00 (CN,EP,US)
Former IPC [2019/11]A61K31/4985, A61K31/5383, C07D471/14, A61K45/06, A61P25/00, A61P25/28
Former IPC [2018/49]A61K31/4985, A61K31/5383, C07D471/14
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/49]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:ORGANISCHE VERBINDUNGEN UND DEREN VERWENDUNG ZUR BEHANDLUNG ODER PRÄVENTION VON ERKRANKUNGEN DES ZENTRALEN NERVENSYSTEMS[2020/52]
English:ORGANIC COMPOUNDS AND THEIR USE IN TREATING OR PREVENTING CENTRAL NERVOUS SYSTEM DISORDERS[2020/52]
French:COMPOSÉS ORGANIQUES ET LEUR UTILISATION DANS LE TRAITEMENT OU LA PRÉVENTION DE MALADIES DU SYSTÈME NERVEUX CENTRAL[2020/52]
Former [2018/49]ORGANISCHE VERBINDUNGEN
Former [2018/49]ORGANIC COMPOUNDS
Former [2018/49]COMPOSÉS ORGANIQUES
Entry into regional phase29.08.2018National basic fee paid 
29.08.2018Search fee paid 
29.08.2018Designation fee(s) paid 
29.08.2018Examination fee paid 
Examination procedure29.08.2018Amendment by applicant (claims and/or description)
29.08.2018Examination requested  [2018/49]
13.02.2019Date on which the examining division has become responsible
06.03.2019Despatch of a communication from the examining division (Time limit: M04)
03.07.2019Reply to a communication from the examining division
18.02.2020Despatch of a communication from the examining division (Time limit: M04)
17.06.2020Reply to a communication from the examining division
08.12.2020Communication of intention to grant the patent
07.04.2021Fee for grant paid
07.04.2021Fee for publishing/printing paid
07.04.2021Receipt of the translation of the claim(s)
Divisional application(s)EP21172297.0  / EP3888656
Opposition(s)22.02.2022No opposition filed within time limit [2022/17]
Fees paidRenewal fee
28.03.2019Renewal fee patent year 03
12.03.2020Renewal fee patent year 04
29.03.2021Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL19.05.2021
CY19.05.2021
EE19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
MC19.05.2021
MK19.05.2021
RO19.05.2021
RS19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
[2024/23]
Former [2024/20]AL19.05.2021
CY19.05.2021
EE19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
MC19.05.2021
RO19.05.2021
RS19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
Former [2022/47]AL19.05.2021
EE19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
MC19.05.2021
RO19.05.2021
RS19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
Former [2022/26]AL19.05.2021
EE19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
RO19.05.2021
RS19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
Former [2022/23]EE19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
RO19.05.2021
RS19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
Former [2022/10]EE19.05.2021
FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
RO19.05.2021
RS19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS22.12.2021
Former [2022/07]FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
RS19.05.2021
SM19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
Former [2021/51]FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
RS19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
IS19.09.2021
Former [2021/49]FI19.05.2021
HR19.05.2021
LT19.05.2021
LV19.05.2021
BG19.08.2021
NO19.08.2021
GR20.08.2021
Former [2021/47]FI19.05.2021
LT19.05.2021
BG19.08.2021
Former [2021/46]FI19.05.2021
LT19.05.2021
Documents cited:Search[A]WO2014110322  (CONCERT PHARMACEUTICALS INC [US]) [A] 1-16 * paragraph [0007] *;
 [A]WO2015154030  (INTRA CELLULAR THERAPIES INC [US]) [A] 1-16 * compound formula (I) * * claims 1, 27-41 *;
 [E]WO2017117514  (TUNG ROGER D [US]) [E] 1-16 * paragraph [0007] - paragraph [0013] * * claims 1, 50, 51, 54-62 *;
 [E]WO2018106916  (CONCERT PHARMACEUTICALS INC [US]) [E] 1-16 * paragraph [0008] - paragraph [0013] * * claims 1, 24, 25, 32-40 *;
 [A]  - ROBERT H. HOWLAND, "Deuterated Drugs", JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES, US, (20150901), vol. 53, no. 9, doi:10.3928/02793695-20150821-55, ISSN 0279-3695, pages 13 - 16, XP055512787 [A] 1-16 * abstract * * page 15, column 3, paragraph 3 *

DOI:   http://dx.doi.org/10.3928/02793695-20150821-55
 [A]  - GRAHAM S TIMMINS, "Deuterated drugs: where are we now?", EXPERT OPINION ON THERAPEUTIC PATENTS, (20140729), doi:10.1517/13543776.2014.943184, ISSN 1354-3776, pages 1 - 9, XP055132523 [A] 1-16 * page 5 - page 7 *

DOI:   http://dx.doi.org/10.1517/13543776.2014.943184
International search[A]US2015079172  (MATES SHARON [US], et al) [A] 1-4, 5/1-4, 6/5/1-4 * ; entire document *;
 [X]WO2015154025  (INTRA CELLULAR THERAPIES INC [US]) [X] 1-4, 5/1-4, 6/5/1-4 * ; paragraph [0090]; claims 1, 9-10 *;
 [A]US2016031885  (LI PENG [US], et al) [A] 1-4, 5/1-4, 6/5/1-4* ; entire document *
by applicantUS4389330
 GB2145422
 US4530840
 US5538739
 WO0035419
 US6548493
 US6552017
 EP0058481
 US6713471
 EP1539115
 US7183282
 USRE39680E
 USRE39679E
 US7238690
 US2008069885
 WO2008112280
 US2009202631
 WO2009114181
 WO2009145900
 WO2011133224
 WO2013155505
 WO2015154025
    - KAY et al., Schizophr. Bull., (19870000), vol. 13, no. 2, pages 261 - 276
 US19690610360
 US20070786935
 WO2008US03340
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.